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Abstract 
Background 
Oxidative stress and glutathione (GSH) metabolism dysregulation has been implicated in the 
pathophysiology of schizophrenia. GAG-trinucleotide repeat (TNR) polymorphisms in the 
glutamate-cysteine ligase catalytic gene (GCLC), the rate-limiting enzyme for GSH synthesis, 
are associated with schizophrenia. In addition, GSH may serve as a reserve pool for neuronal 
glutamate (Glu) through the -glutamyl cycle. The aim of this study is to investigate brain 
[GSH] and its association with GCLC polymorphism, peripheral redox indices and brain Glu. 
Methods 
Magnetic resonance spectroscopy was used to measure [GSH] and [Glu] in the medial 
prefrontal cortex (mPFC) of 25 early-psychosis patients and 33 controls. GCLC polymorphism 
was genotyped, glutathione peroxidases (GPx) and glutathione reductase (GR) activities were 
determined in blood cells.  
Results 
Significantly lower [GSHmPFC] in GCLC high-risk genotype subjects were revealed as 
compared to low-risk genotype subjects independent of disease status. In male subjects, 
[GSHmPFC] and blood GPx activities correlate positively in controls (p = 0.021), but negatively 
in patients (p = 0.039). In GCLC low-risk genotypes, [GlumPFC] are lower in patients, while it 
is not the case for high-risk genotypes. 
Conclusions 
GCLC high-risk genotypes are associated with low [GSHmPFC], highlighting that GCLC 
polymorphisms should be considered in pathology studies of cerebral GSH.  Low brain GSH 
levels are related to low peripheral oxidation status in controls but with high oxidation status in 
patients, pointing to a dysregulated GSH homeostasis in early psychosis patients.  GCLC 
polymorphisms and disease associated correlations between brain GSH and Glu levels may 
allow patients stratification.  
Keywords: schizophrenia, glutathione, oxidative stress, MRS, GCLC, glutamate, redox, 
glutathione peroxidase. 
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Introduction 
Schizophrenia is a major psychiatric disorder which results from a complex interplay between 
genetic and environmental risk factors during neurodevelopment. There is increasing evidence 
suggesting that oxidative stress and dysregulation of the glutathione (GSH) metabolism play a 
role in the pathophysiology of the disease 1-4. GSH serves as a major cellular redox regulator 
and antioxidant protecting cell from damages induced by reactive oxygen species. Decreased 
[GSH] have been reported in cerebro-spinal fluid (-27%) of patients with chronic 
schizophrenia5. A postmortem study also revealed lower caudate [GSH] in treated patients than 
in control subjects 6. Furthermore, similar reduction of [GSH] was observed in blood plasma of 
treated and untreated patients 7-10.  
Studies of cerebral [GSH] in vivo in schizophrenia are limited and exclusively achievable by 
using 1H magnetic resonance spectroscopy (MRS). Do et al. reported a 52% reduction of [GSH] 
in medial prefrontal cortex of chronic schizophrenia patients at 1.5T (14 controls and 14 
patients, in 5; extended to 18 controls and 20 patients, unpublished results).  However, two 
consecutive studies in schizophrenia patients did not reveal significant GSH alterations in the 
anterior cingulate cortex at 4T (9 controls and 11 patients) 11 or in posterior medial frontal 
cortex at 3T (16 controls and 20 patients), though low [GSH] in this later region were associated 
with more severe negative symptoms 12. Reasons for such inconsistencies remain unclear. 
Differences in methodological aspects, such as magnetic field strengths, pulse sequences, 
number of subjects, and stage of disease may be relevant. 
Whether alterations of cerebral [GSH] are already present in the early phase of psychosis (EP) 
remains an open question. Only one study has reported 22% higher [GSH] in medial temporal 
lobe of first episode patients using PRESS 1H MRS sequence at 3T 13. However, the mean 
Cramer-Rao lower-bound (CRLB) for the corresponding measurement of GSH was moderately 
high (~21%). Therefore, further investigations of cerebral [GSH] in EP patients including those 
in other brain regions are required.  
One genetic factor has been reported to influence [GSH] in the periphery: a GAG trinucleotide 
repeat (TNR) polymorphism in the gene coding for the catalytic (GCLC) subunit of glutamate-
cysteine ligase (GCL), the rate-limiting enzyme for GSH synthesis. Importantly, this 
polymorphism was associated with schizophrenia in two case-control studies 14: the GCLC 
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high-risk genotypes (i.e. with 7/8, 8/8, 8/9 and 9/9 TNR) were more frequent in patients (30%) 
and were associated with lower GCLC protein expression, GCL activity and [GSH] in 
fibroblasts when challenged with oxidative stress conditions, as compared with GCLC low-risk 
genotypes (i.e. with 7/7 and 7/9 TNR). However, the peripheral GSH levels may not reflect 
GSH status in the central nervous system and the association between cerebral GSH levels and 
GCLC polymorphism has never been investigated. The understanding of their relation may shed 
light on current discrepancies concerning cerebral [GSH] in psychotic patients.  
Studies on the various antioxidant systems in the peripheral tissue of schizophrenia patients 
showed large discrepancies 1, 4. Altered levels of scavenging antioxidant enzymes were 
reported, however with mixed results 15. Glutathione peroxidases (GPx) are important 
antioxidant enzymes that eliminate hydrogen and lipid peroxides by converting GSH into 
oxidized GSH (GSSG). Then GSSG is reduced back to GSH by glutathione reductase (GR) 
(Figure 1s). The precise quantification of blood GSH/GSSG balance in a psychiatric clinical 
setting is quite challenging and subjected to artefactual oxidations leading to unreliable 
results16. To capture the (dys)regulation of redox status, we assessed enzymatic activities of 
GPx and GR as well as their ratio (GPx/GR) in blood cells instead of GSH/GSSG ratio..  
Besides its antioxidant properties, the tripeptide GSH has been proposed to constitute a reserve 
pool for neuronal glutamate (Glu) through the -glutamyl cycle 17. -glutamyltranspeptidase 
(GGT) transfers -glutamyl moiety of extracellular GSH to an acceptor amino acid, generating 
-glutamyl amino acid and cysteinylglycine. On the one side, the cysteinylglycine can then 
provide substrates to synthesize GSH; on the other side, -glutamyl amino acid can be 
metabolized to amino acid and 5-oxoproline, which can be further catalyzed by the 5-
oxoprolinase to form Glu, a precursor of GSH 18, 19. The inhibition of 5-oxoprolinase reduces 
[Glu] in cortical and hippocampal neurons, with no changes in [GSH] 17. This mechanism is of 
high interest in the context of the glutamatergic hypothesis in schizophrenia 20, and has never 
been evaluated in vivo in humans. 
Therefore, the aims of this study were 1) to assess [GSH] in medial prefrontal cortex of early 
psychosis patients relative to control subjects 2) to test its association with GAG-TNR of GCLC 
genotypes and 3) with peripheral GSH redox indices (GPx, GR activities and their ratio 
GPx/GR) and finally, 4) to investigate the relationship between brain GSH and Glu. 
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Methods and Materials 
Subjects 
Twenty-five early psychosis patients (within the  first 3 years of treatment for a psychotic 
disorder and having met psychosis threshold according to the Comprehensive Assessment of 
At Risk Mental States criteria) 21 were recruited from the Treatment and Early Intervention in 
Psychosis Program (TIPP, University Hospital of Lausanne, Lausanne, Switzerland) 22. 
Medication prescribed to patients followed international recommendations for early psychosis 
treatment 23, was recorded in the medical file and adherence to treatment was rated by clinicians. 
CPZ equivalents were calculated on the basis of formulas using regression with power 
transformation suggested by Andreasen et al. 24 and of maximum daily doses 25 for the 
remaining medication (table 1). 
Onset of illness was defined as the time when a definite diagnosis of psychosis was reached by 
the presence of clear evidence of delusions, hallucinations, first rank symptoms, catatonic 
symptoms for at least one week on the basis of elements gathered by treating psychiatrist and 
case managers through interviews with patients, their relatives and any mental health 
professional who would have been involved in the care of the patient at that time. Duration of 
illness was defined as the time that elapsed between onset of illness and the time when MRI 
was performed. Diagnosis for patients was based on DSM-IV criteria and is the result of an 
expert consensus procedure based on information gathered over the three years of treatment. 
Thirty-three age, sex matched healthy controls were recruited and assessed by the Diagnostic 
Interview for Genetic Studies 26 with the following exclusion criteria: having major mood, 
psychotic, or substance-use disorder and a first-degree relative with a psychotic disorder. 
Neurological disorder and severe head trauma were exclusion criteria for all subjects. 
Demographic and clinical details of all participants are shown in table 1. All participants gave 
informed written consent prior to participate in this study which was approved by the ethics 
review board of the Lausanne University Hospital. 
1H Magnetic Resonance Spectroscopy 
6 
All MRS measurements were carried out on a 3T MR scanner (Magnetom TimTrio, Siemens 
Healthcare, Erlangen, Germany) with a transverse electromagnetic (TEM 3000) head coil (MR 
Instruments, Inc., Minneapolis, MN, USA). The magnetic field homogeneity was optimized by 
adjusting first- and second-order shims using FAST(EST)MAP 27, 28. In vivo 1H MR spectra 
were acquired from a volume of interest (VOI = 20x20x25mm3) positioned in the medial 
prefrontal cortex (mPFC; Fig. 1A) using a short-TE spin-echo full-intensity acquired localized 
single voxel spectroscopy technique (SPECIAL) 29, 30. The following scan parameters were 
used: TE/TR = 6/4000 ms, acquisition bandwidth = 2 kHz, number of averages = 148, vector 
size = 2048. Outer volume suppression (OVS) 31 and water suppression with variable-pulse 
power and optimized relaxation delays (VAPOR) 32 were applied prior to the SPECIAL 
localization sequence. 
In addition, to evaluate tissue composition inside the VOI, three-dimensional T1-weighted 
anatomical images were obtained using a magnetization-prepared rapid gradient-echo 
(MPRAGE) sequence 33 with a 32-channel head array coil, TE/TR = 2.98/2300 ms, TI = 900 
ms, flip angle = 9 degree, FOV = 240×256 mm2, matrix = 240×256, slice thickness = 1.2 mm. 
Spectral quantification 
[GSHmPFC] and [GlumPFC] were obtained by analyzing water suppressed in vivo 
1H MR spectra 
using LCModel (Stephen Provencher, Inc., Oakville, ON, Canada) 34 with a basis-set consisting 
of 20 simulated individual metabolite spectra: alanine(Ala), aspartate (Asp), phosphocreatine 
(PCr), creatine (Cr), -aminobutyric acid (GABA), glutamine (Gln), Glu, phosphorylcholine 
(PCho), glycerophosphorylcholine (GPC), GSH, glucose (Glc), lactate (Lac), glycine (Gly), 
myo-inositol (mIns), N-acetylaspartylglutamate (NAA), N-acetylaspartylglutamate (NAAG), 
ascorbate (Asc), phosphorylethanolamine (PE), scyllo-inositol (Scyllo), taurine (Tau), and a 
experimentally measured macromolecule baseline 35. The spectral fit obtained from LCModel 
is a linear combination of model spectral provided in the basis-set and the estimation of fitting 
error is provided by CRLB. Unsuppressed water 1H MR spectra were used as an internal 
reference for the quantification of metabolite concentrations. The spectral range for analysis 
was set to 0.2 - 4.2 ppm. Tissue composition inside the VOI was calculated based on the 
segmentation of 3D T1-weighted anatomical images using an in-house software 
36. Water 
concentrations, used in LCModel analysis, were calculated based on the volume fractions of 
white matter (WM), grey matter (GM) and cerebrospinal fluid (CSF) assuming water 
concentrations of WM, GM and CSF are 35880, 43300 and 55556 mM, respectively. Metabolite 
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concentrations were then divided by the fraction of WM and GM to correct for CSF inside the 
VOI, since metabolites are mainly present in WM and GM 37. The signal-to-noise ratio (SNR) 
was obtained using NAA peak height at 2.01 ppm divided by the standard deviation of the noise. 
Genotyping of GCLC tri-nucleotide polymorphism 
DNA was extracted from whole blood. PCR was performed according to Walsh et al. 38  and 
modified as in Gysin et al. 14: in a 20 L reaction mix with GoTaq polymerase, 1.5 mM MgCl2, 
0.25 M of each primer (forward: TTCTGCGGGCGGCTGAGTGTCC; reverse: 
ATGGCGCTTGGTTTCCTCCC), 0.2mM of dNTP and 100 ng of genomic DNA. 
Amplification temperature were: 95° for 2 min followed by 32 cycles of  95° for 30 s, 62° for 
30 s, 72° for 1 min and 1 step at 72° for 5 min . PCR products were separated on 10% 
polyacrylamide gels and were visualized under UV after 15min staining in GelRed solution. 
Classification into GCLC high- or GCLC low-risk genotype is based on the number of GAG 
repeats as defined in Gysin et al. (7/8, 8/8, 8/9, 9/9 and 7/7, 7/9 respectively) 14.  
[GSHB], GPx and GR enzymatic activities in blood 
Blood was collected by venipuncture in Vacutainer-tubes coated with Li-heparinate (Becton 
Dickinson), between 7 and 8:30 AM under restricted activity conditions and fasting from the 
previous midnight. An aliquot of whole blood is sampled and frozen at -80°C until analysis of 
[GSHB]. [GSHB] was measured in 45 L of whole blood using a diagnostic kit and according 
to manufacturer instructions (Calbiochem); [GSHB] are normalized to blood volume. Blood 
cells were prepared as in 14. All manipulations were performed rapidly with cooling to avoid 
artefactual oxidation of thiol compounds. Essentially, GR activity 39 was assessed in 8 L of 
hemolyzed blood incubated in a phosphate buffer solution (100 mM, pH7.5) with EDTA (0.6 
mM), oxidized glutathione (2.5 mM), NADPH (0.25 mM). GPx activity 40 was assessed in 8 
L of hemolyzed blood incubated in phosphate buffer solution (100 mM, pH7.5) with 
EDTA(0.6 mM), glutathione (2.5 mM), NADPH (0.25 mM), GR (0.84 U/ml; Fluka) and Tert-
butyl hydroperoxide (0.8 mM, Fluka). Enzymatic activities were determined in triplicates as a 
function of the decrease in NADPH measured at 340 nm and normalized to hemoglobin content. 
Statistical analysis  
Differences between patients and controls in sex, smoking and handedness were assessed using 
Chi-square test or fisher’s exact test accordingly. Differences in age, education of parents, 
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fractions of WM, GM and CSF, spectral quality (SNR and linewidth) between patients and 
controls, [GSHmPFC] between smokers and non-smokers were evaluated by unpaired t-test (two-
tailed). The effects of GCLC GAG-TNR polymorphism (low-risk versus high-risk), disease 
(controls versus patients), sex (male versus female) and age on [GSHmPFC], [GSHB], blood GPx 
and GR activities were investigated using generalized linear model in Matlab (R2013b,The 
MathWorks, Inc. USA). Two-tailed Mann-Whitney test was used to investigate the alterations 
in [GlumPFC]. All correlation tests were performed using the Spearman rank correlation (two-
tailed) in GraphPad Prism (Version 5.04, GraphPad Software, Inc., USA). The difference 
between two independent correlation coefficients was tested online (Preacher, K. J. (2002, 
May). Calculation for the test of the difference between two independent correlation 
coefficients [Computer software]. Available from http://quantpsy.org.). 
Results 
There were no statistical differences in age, sex, handedness and education of parents between 
patients and controls indicating a good matching for these criteria (Table 1). All individuals 
were Caucasian. Since the high prevalence of smoking in schizophrenia patients 41, we also 
observed more smokers in patients.  
 A representative short-TE 1H MR spectrum obtained from mPFC, LCModel spectral fit and 
individual metabolites fits are shown in Fig 1B. [GSHmPFC] were measured by short-TE 
1H 
MRS at 3T and quantified using LCModel yielding CRLB of 10 ± 3% (mean ± s.d.). In addition 
to GSH, other 12 metabolites were quantified from LCModel fitting including Asp, Cr, PCr, 
Gln, Glu, Ins, NAA, total Choline (GPC+PCho) with mean CRLBs < 10% and GABA, Lac, 
PE, Tau with mean CRLBs < 20%. Spectral SNR and linewidth (LCModel output) were 104 ± 
16, 0.031 ± 0.005ppm for controls and 97 ± 12, 0.033 ± 0.006ppm for patients, respectively. 
No significant differences (p > 0.05) in spectral quality (i.e. SNR and linewidth) between groups 
were observed. Tissue compositions inside the MRS voxel were measured and there is no 
differences of WM, GM and CSF fractions between patients and controls (Table 1s).  
GSH levels in mPFC 
To discern [GSHmPFC] changes in early psychosis and its association with GCLC 
polymorphism, GCLC genotypes were included as a covariant together with age and sex to test 
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whether [GSHmPFC] were different between 25 EP patients and 33 controls. There were 
significantly lower [GSHmPFC] in subjects with the GCLC high-risk genotypes (1.15 ± 0.17 
mol/g) as compared to those with low-risk genotypes (1.34 ± 0.25mol/g; p = 0.006; Fig. 2), 
independent of the disease status (p > 0.05), age (p > 0.05) and sex (p > 0.05). To study the 
potential effect of medication, illness duration and smoking, we first correlated [GSHmPFC] with 
CPZ equivalents and disease duration. No significant correlations were found between them (p 
> 0.05). [GSHmPFC] were further compared between smokers and non-smokers, no significant 
difference was revealed (p > 0.05). Including smoking as one covariant showed no effect on the 
result and [GSHmPFC] association with GCLC polymorphism still remained significant (p = 
0.006). 
To decipher whether blood GSH reflects cerebral GSH, we studied the relationship between 
them. No correlation was found between [GSHB] and [GSHmPFC] (Supplementary Fig. 1s) and 
[GSHB] were not affected by disease, age, sex and GCLC polymorphism (Supplementary Table 
2s). 
Relationship between [GSHmPFC] and [GlumPFC] 
We revealed that [GSHmPFC] were affected by GCLC polymorphism and additionally GSH may 
serve as a reservoir for neuronal Glu 17, which is involved in the NMDA hypofunction 
hypothesis of schizophrenia. Therefore, we evaluated [GlumPFC] (CRLB of 2.0 ± 0.5%) between 
patients and controls in GCLC low-risk and high-risk group respectively and revealed a 8 % 
reduction of [GlumPFC] in GCLC low-risk patients relative to low-risk controls (p  = 0.01), while 
no difference was found between high-risk genotypes in controls and patients (Fig. 3A). In 
GCLC low-risk controls, [GlumPFC] positively correlated with [GSHmPFC] (r = 0.5133, p = 0.010; 
Fig. 3B); however this correlation was absent in low-risk genotypes in patients. Interestingly, 
correlations were observed neither in controls nor in patients with high-risk genotypes (Fig. 
3C).  
Correlation between brain GSH and peripheral redox enzymatic activities 
To test the association between cerebral GSH and peripheral redox indices, we investigated 
enzymatic activities of GPx and GR in blood cells, and their correlations with [GSHmPFC]. No 
significant differences were observed for GPx and GR activities between patients and controls, 
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nor between GCLC high-risk and low-risk genotype (Supplementary Table 2s). Female subjects 
showed higher GR activities than male subjects (p = 0.015, Table 2s), which is consistent with 
42, therefore, following analyses were performed separately for each sex group. 
[GSHmPFC] were positively correlated with GPx activities in male controls (Fig. 4A; r = 0.5543, 
p = 0.021). In contrast, in male patients an inverse correlation was obtained between [GSHmPFC] 
and GPx activities (Fig. 4D; r = -0.4899, p = 0.039). There is a trend of a positive correlation 
between GR activities and [GSHmPFC] in male controls (Fig. 4B; r = 0.3973, p = 0.114) but not 
in male patients (Fig.  4E; r = 0.0111, p = 0.966). The ratio of GPx/GR activity, which reflects 
the regulation of redox status, tends to correlate negatively with [GSHmPFC] in male patients 
(Fig. 4F; r=-0.4760, p=0.0534), whereas such correlation was absent in male controls (Fig. 4C). 
We further tested the significance of the difference between patients and controls for the 
correlation coefficients of [GSHmPFC] with GPx activities, and with GPx/GR ratio. Patients and 
controls demonstrated significant differences in correlation coefficients of [GSHmPFC] with GPx 
activities (z=2.07, p=0.002) and with GPx/GR ratio (z=2.18, p=0.029). For female controls or 
patients, we did not observe any significant correlations (Supplementary Fig. 2s).  
Discussion 
In this study, we assessed [GSHmPFC] of 25 early psychosis patients and 33 control subjects. We 
showed that GAG-TNR polymorphisms in GCLC, which have been previously linked to 
schizophrenia, are associated with [GSHmPFC] irrespectively of disease status. Additional 
analyses also revealed that correlation between cortical GSH levels and peripheral redox 
marker, i.e. blood cells GPx enzymatic activities, differed in patients and controls: their 
correlation is positive in controls and negative in patients. Low [GSHmPFC] are associated with 
low peripheral oxidation status in controls but with high oxidation status in patients, suggesting 
a dysregulation of GSH homeostasis under oxidative conditions. Furthermore, in GCLC low-
risk genotypes, [GlumPFC] are lower in patients as compared to controls, while it is not the case 
for GCLC high-risk genotypes. This suggests a predominant pathogenic role of glutamatergic 
system impairments in GCLC low-risk genotypes. 
In vivo measurement of cerebral GSH 
The in vivo measurement of GSH concentration in human brain using (short-TE) 1H MRS is 
challenging because of its low concentration and strong spectral overlap mainly with resonances 
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e.g. originated from glutamate and glutamine. Therefore, spectral editing schemes 43-45 
combined with localization sequences have been developed for the detection of GSH. Although 
an editing approach provides a resolved measurement of GSH, several downside aspects 
remain, such as signal reduction induced by editing efficiency 44, sensitive editing performance 
to the frequency drift of the narrow band editing pulse 46, T2 relaxation assumption for 
quantification and restricted number of measureable metabolites 44. As an alternative approach, 
short-TE MRS has been employed to detect GSH at 3T and above 11, 29, 47, 48. The main benefit 
of short-TE MRS, apart from GSH measurement, is the possibility to simultaneously assess a 
large number of metabolites. Nevertheless, due to spectral overlap, GSH quantification relies 
on deconvolution methods such as LCModel 34. In the current study, we performed GSH 
measurement by short-TE 1H MRS to obtain other metabolic information, e.g. Glu, in parallel. 
A previous validation study of Terpstra et al. compared GSH measurements using both, MEGA-
PRESS and short-TE STEAM methods, at 4T and demonstrated a good agreement between 
these two methods 11. Recently, Wijtenburg et al. showed an excellent reproducibility of GSH 
measurement using short-TE MRS at 3T 48.  We further evaluated the accuracy and precision 
of GSH measurement by the short-TE MRS method at 3T showing that comparable spectral 
quality in terms of SNR and linewidth would allow the accurate measurement of GSH changes 
between groups 49. Therefore, the matched spectral quality is a prerequisite for the detection of 
GSH alterations. This requirement was well satisfied in this work as judged from equivalently 
high spectral quality of both patient and control groups. 
Association of [GSHmPFC] with GCLC polymorphism 
The current study provided the original finding that GCLC high-risk genotypes are associated 
with low [GSHmPFC]. The functional impact of short GAG repeats on GCLC regulation is still 
being debated: at the molecular level, a recent study suggested that the length of the TNR 
modulates mRNA translation 50, but it is controversial whether longer repeats increase or 
decrease GCLC and subsequently GSH levels. Interestingly, Nichenametla et al. suggest that 
the effect might be cell and tissue specific. Indeed, in vitro 50, in tumor cell lines 51, and in 
mononuclear blood cells 50, the 7/7 genotype (i.e. GCLC low-risk) is associated with low GSH 
and low GCL activity as compared to 9/9 genotype (i.e. GCLC high-risk). But in other systems, 
such as red blood cells or fibroblasts, submitted to oxidative stress the regulation is opposite: 
7/7 genotype display more GSH and higher GCL activity than 9/9 genotype 14, 50, 52. Similarly, 
we now show that GCLC low-risk genotypes (7/7 and 7/9) are associated with higher [GSHmPFC] 
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than high-risk genotypes (9/9, 8/8, 8/9, 7/8). Therefore, our study highlights which type of 
regulation is linked with GAG repeats in cerebral cortex. Since GCLC high-risk genotypes were 
more frequent in patients 14, this result may thus clarify the potential implication of GCLC high-
risk genotypes in psychiatric diseases.  
In addition, this polymorphism in GCLC could be a plausible reason for not revealing [GSHmPFC] 
changes in the patient cohort of the current study, i.e. group differences depend on the 
proportion of the various GAG-TNR genotypes. Indeed, in contrast to the larger cohort of 
patients with chronic schizophrenia previously studied, in which the GCLC high-risk genotypes 
were more frequently observed in the disease group 14, this is not the case for the present small 
sample in which the percentage of high-risk controls subjects (27%) was similar to that of EP 
patients (31%). Importantly, this could thus be an explanation for inconsistent results observed 
for brain GSH levels in schizophrenia patients, i.e. essentially different GAG-TNR genotypes 
distribution in the very small cohorts of previous studies leading to discrepancies. In this regard, 
it is important to note that allele frequencies vary strongly with the ethnic background and 
therefore not controlling for this factor may induce bias 52, 53. In the context of a redox 
dysregulation hypothesis in schizophrenia pathophysiology 2, 3, the presence of GCLC high-
risk genotypes in the control population suggests the possibility of a protective factor in healthy 
subjects carrying these variants.  
Moreover, stratification of patients based on this genetic marker may help identifying distinct 
pathogenic mechanisms in GCLC low-risk vs high-risk schizophrenia patients. Indeed, in 
GCLC low-risk individuals [GlumPFC] are lower in patients as compared to controls, while it is 
not the case in GCLC high-risk genotypes (Fig. 3A). Furthermore, a positive correlation was 
found between [GlumPFC] and [GSHmPFC] in GCLC low-risk controls, but not in low-risk 
patients (Fig. 3B). This contrasts with GCLC high-risk genotypes, in which the tight correlation 
between [GSHmPFC] and [GlumPFC] is absent both in controls and patients (Fig. 3C). However 
the latter result was based on a small number of high-risk subjects; a relationship between brain 
GSH and Glu levels may emerge with a larger number of subjects. Together, these data suggest 
that aberrant functions of enzymes in the -glutamyl cycle or other glutamatergic system 
impairments may be critical, at least in GCLC low-risk patients. Note that Glu and GSH were 
both quantified using water as an internal reference, therefore, water can be a potential driving 
factor in the correlation between GSH and Glu. However, such effect should be general for all 
13 
groups, yet we did not see a correlation e.g. in low-risk patients, suggesting that such an effect 
is likely of limited importance. 
The present study did not reveal altered [GSHmPFC] in early psychosis patients and therefore 
contrasts with findings in patients with chronic schizophrenia5. Apart from the genetic factor 
mentioned above, other hypothesis can be mentioned 1) GSH measurement was performed 
under resting conditions and alterations that can be reliably measured may only appear under 
particular conditions, such as psychological stress, which leads to oxidative stress at cellular 
levels 54. Indeed, lower [GSH] in fibroblasts of GCLC high-risk subjects as compared to low-
risk genotypes were only observed under oxidative stress conditions, suggesting a deficit in the 
induction of regulatory mechanisms or adaptive responses. 2) GSH concentration determination 
by MRS does not allow the discrimination of GSH in the neuronal, glial or extracellular pools 
55. As [GSH] is about ten times higher in astrocytes than in neurons, a differential neuronal
regulation might be masked. 3) Early psychosis patients might have an intermediary phenotype 
between control subjects and patients with chronic schizophrenia. There could be a stage 
specificity for oxidative stress in the brain: alterations of cerebral [GSH] might be more 
prominent in chronic phase of the disease, while soluble superoxide dismutase-1 defects have 
recently been suggested to be an early phase marker 56. Importantly, our data indicates that 
medication and smoking are probably not biases, as we did not find a correlation between 
[GSHmPFC] and CPZ equivalents, and as a covariant smoking has no effects on [GSHmPFC] and 
the current results. There is a possibility that antipsychotics may have antioxidant effect and 
raise GSH to levels comparable to healthy controls. However no difference in [GSHmPFC] 
between medicated (n=20) and few non-medicated patients (n=5) was observed (p=xxx). The 
medication effect on cerebral GSH levels has never been documented, thus requiring further 
investigation. 
Dysregulated GSH redox activity in patients 
Glutathione is critically involved in redox regulation: A balanced activity of GPx to eliminate 
peroxides by metabolizing GSH and of GR to recycle GSH is crucial to maintain GSH 
homeostasis (see fig. 1s). Disturbed GSH redox coupling with the antioxidant defense system 
was suggested in the postmortem caudate, supported by the lack of correlations between GSH 
and GPx or GR in patients 6.  Our study indicates similar defects of redox regulation in vivo in 
early psychosis (Fig. 4). In male subjects, blood GPx activities and brain GSH levels correlate 
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negatively in patients (Fig. 4D), but positively in controls (Fig. 4A) with a significant difference 
between the two correlation coefficients. Similarly, we observed a trend of inverse correlation 
between blood GPx/GR enzymatic ratio and brain GSH levels in patients (Fig. 4F) but not in 
controls (Fig. 4C), with a significant difference between the two correlation coefficients. On 
the other hand, blood GR activities and brain GSH levels were not correlated in both patients 
and controls. These correlation analyses of brain GSH levels with blood GPx and GPx/GR 
activities imply a proper regulation of the redox balance in controls and a disrupted redox 
homeostasis in patients. Specifically, low brain GSH levels are associated with low peripheral 
oxidation status in controls but with high oxidation status in patients, as indicated by their high 
blood GPx activities, pointing to a dysregulated GSH homeostasis under oxidative conditions 
in early psychosis patients.  
Lack of link between peripheral and central GSH levels 
The lack of relationship between [GSHB] and [GSHmPFC] is consistent with the reported lack of 
significant transport system for GSH across the blood brain barrier 57. Moreover peripheral 
GSH levels measurements showed large discrepancies in the literature due to not only 
differences in analytical methodologies but also in testing materials (whole blood vs. serum vs. 
blood cells vs. plasma), exposure to medication (drug naïve vs. drug withdrawal vs. medicated), 
stages of the disease (early psychosis vs. chronic or active vs. remission phase), lifestyle or 
dietary pattern 1. It is also important to note that blood GSH levels are susceptible to artefactual 
oxidation during preparation and longtime storage of samples, unless special care is taken to 
prevent it immediately after blood collection (cold conditions, thiol blocking reagents…), 
measures difficult to guarantee in psychiatric clinical settings. To our knowledge, the present 
study is the first allowing a comparison between [GSHB] and [GSHmPFC] revealing that they are 
not correlated. This suggests that peripheral GSH levels unlikely reflects brain levels, in 
keeping with Wu et al58 and the reported predominant liver origin of blood GSH59, 60. Raffa et 
al. reported decreased plasma GSH levels in drug naïve first episode patients 9, 10.  On the other 
hand,  in the current study in which maximal care was taken to minimize artefactual factors 
during blood collection and processing, no difference was found in total blood GSH levels 
(blood cells + plasma) of medicated patients in the early phase of psychosis versus matched 
controls. Indeed, GSH levels quantification in total blood was chosen instead of plasma levels 
as the latter are susceptible to more variability due to the interference of high intracellular GSH 
due to hemolysis61. In regards to relationship to GCLC genotypes, we did not observe 
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differences in [GSHB] between long and short repeats, which may be ascribed to the fact that 
we assessed the free GSH instead of both free and protein bound GSH as measured in 50. This 
result is consistent with our previous study in chronic SZ patients61 showing no link between 
blood GSH levels and GCLC genotypes (unpublished data).  
Limitations 
This study has some limitations. Firstly, given their later age of onset, the number of female 
patients is relatively small in the current study, thus affecting the generality of the result of 
regulation of GSH redox activity. Therefore future study with more female patients is required 
for further investigation of GSH redox regulation in female cohort. Secondly, GCLC high-risk 
subjects represent about 30% of the patient population14. As we do not know the genotype at 
the time of recruitment, it is challenging to recruit high number of GCLC high-risk subjects. 
Lastly, the potential medication effect is a general confounding factor for most schizophrenia 
patients studies, although we did not observe differences in GSH levels between medicated and 
unmedicated patients, 
Conclusions 
We show for the first time that GAG-TNR of GCLC gene affects [GSHmPFC], with high-risk 
genotypes associated with low [GSHmPFC]. These results extend to the central nervous system 
previous results in fibroblasts 14 and in red blood cells 50, therefore highlight that GCLC 
genotypes should be taken into account for the investigation of cerebral GSH levels in any 
pathology studies. Moreover, low [GSHmPFC] are associated to low peripheral oxidation status 
in controls but with high oxidation status in patients, pointing to a dysregulated GSH 
homeostasis in early psychosis patients and paving the way for the search of central and 
peripheral markers of the disease. Lastly, GCLC polymorphisms and disease associated 
correlations between [GlumPFC] and [GSHmPFC] may allow the stratification of patients and open 
new avenues to biomarker guided treatment strategies. 
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Figure caption 
Figure 1. (A) T1-weighted MPRAGE images with the volume of interest (20x20x25mm
3) for 
MRS in the medial prefrontal cortex.  (B) A representative 1H MR spectrum acquired with the 
SPECIAL sequence at 3T (TE/TR = 6/4000 ms, number of averages = 148), the corresponding 
LCModel spectral fit, fit residual, macromolecules, baseline and individual metabolite fits 
including GSH. 
Figure 2. [GSHmPFC] are lower in GCLC high-risk genotypes (7/8, 8/8, 8/9 and 9/9; n = 17) than 
in low-risk genotypes (7/7 and 7/9; n = 41). From left to right: [GSHmPFC] in low-risk genotype 
controls, low-risk genotype patients, high-risk genotype controls and high-risk genotype 
patients, respectively. Each horizontal bar indicates the mean value of the group. ** p=0.006. 
Figure 3. (A) [GlumPFC] in GCLC low-risk controls (n=24), low-risk patients (n=17), high-risk 
controls (n=9) and high-risk patients (n=8). The bars represent mean values of each data group. 
* p<0.05. Different associations between [GSHmPFC] and [GlumPFC] in GCLC low-risk (B) and
high-risk (C) subjects. In GCLC low-risk controls, [GSHmPFC] positively correlated with 
[GlumPFC]. The correlations between [GSHmPFC] and [GlumPFC] were absent in GCLC low-risk 
patients, high-risk controls and high-risk patients. 
Figure 4. Correlations between [GSHmPFC] and blood redox enzymatic activities of GPx, GR 
and ratio GPx/GR in male controls (n=17) and in male patients (n=17). [GSHmPFC] were 
positively correlated with GPx activities in controls (A). Conversely, in patients [GSHmPFC] 
were negatively correlated with GPx activities (D). There is a trend of positive correlation 
between GR activities and [GSHmPFC] in controls (B) but not in patients (E). The ratio of 
GPx/GR activity, reflecting the regulation of redox status, correlated negatively with [GSHmPFC] 
in patients (F) not in controls (C). 
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Table 1 Demographic characteristics of controls and early psychosis patients.
Controls (n=33) Patients (n=25) p value
Age, years (mean ± s.d.) 25.4 ± 4.5 24.8 ± 6.1 n.sa
Sex, Male/Female 18/15 18/7 n.sb
Ethnicity Caucasian Caucasian -
Education of parents, years (mean ± s.d.) 14.4 ± 3.6 15.1 ± 4.6 n.sa
Cigarettes, smokers/non-smokers 4/29 13/12 0.001b 
Handedness, Right/Left/Ambidextrous 28/5/0 22/2/1 n.sc
Illness duration, days (mean ± s.d.) - 933 ± 867 -
CPZ equivalents, mg (mean ± s.d.) - 325 ± 317d -
Antipsychotic medications 
Amisulpride 3 
Aripiprazole 5 
Clozapine     1 
Olanzapine    2 
Paliperidone 1 
Quetiapine    5 
Risperidone  3 
None     5 
aUnpaired two tailed Student t test; bchi-square; cfisher’s exact test; dfive patients without antipsychotic 
medication; CPZ equivalents, chlorpromazine equivalents; n.s., not significant (p > 0.05), s.d., standard 
deviation. 
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Figure 1s. Glutathione (GSH) redox cycle for eliminating reactive oxygen 
species(ROS). The ROS such as hydrogen peroxide can be reduced by GSH 
peroxidase (GPx) through converting GSH to oxidized GSH (GSSG). Then 
GSSG is reduced back to GSH by GSH reductase (GR ).
  
Figure 1s. No correlation between [GSHmPFC] and [GSHB]  (n=57). 
 
Figure 2s.  No correlation between [GSHmPFC] and blood enzymatic activities of GPx , GR and GPx/GR in 
female controls (n=15; A-C) and in female patients (n=7; D-F).  
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Table 1s. Tissue compositions of the MRS voxel. 
Tissue fraction (%) Controls (n=33) Patients (n=25)  p value 
White matter  23.5 ± 4.1 23.5 ± 4.4  n.s. 
Grey matter 59.1 ± 3.5 57.5 ± 5.2  n.s. 
Cerebrospinal fluid 17.3 ± 2.8 18.9 ± 4.6  n.s. 
P values obtained from unpaired two tailed Student t test; n.s., not significant.  
 
Table 2s. P values obtained from generalized linear model to test the effects of disease(controls versus 
patients), gender (male versus female), age and GCLC GAG-TNR polymorphism (low-risk versus high-risk) on 
blood GPx, GR activities, GPx/GR ratio and blood GSH. * p<0.05. 
 
GPx activity 
(mol/min/g of Hb) 
GR activity 
(mol/min/g of Hb) 
GPx/GR  
[GSHB] 
(mol/ml of total blood) 
Disease 0.154 0.794 0.289 0.928 
Gender 0.258 0.015* 0.549 0.973 
Age 0.077 0.076 0.154 0.246 
GCLC polymorphism 0.583 0.867 0.444 0.592 
 
Table 3s.  mPFC Glu and GSH levels in different groups. 
 
Patients 
(n=25) 
Controls 
(n=33) 
Male 
(n=36) 
Female 
(n=22) 
High-risk 
(n=17) 
Low-risk 
(n=41) 
Treated 
patients 
(n=20) 
Untreated 
patients 
(n=5) 
GSH, mol/g 
(mean ± s.d.) 
1.28 ± 0.26 1.29 ± 0.23 1.30 ± 0.26 1.25 ± 0.22 1.15 ± 0.17 1.34 ± 0.25 1.31 ± 0.26 1.15 ± 0.24 
Glu, mol/g 
(mean ± s.d.) 
13.47 ± 1.59 14.18 ± 0.98 13.87 ± 1.36 13.88 ± 1.28 13.87 ± 0.76 13.88 ± 1.49 13.74 ± 1.60 12.4 ± 1.13 
 
